BR112012009121A2 - Novas composições para a prevenção e/ou tratamento de distúrbios degenerativos do sistema nervoso central - Google Patents

Novas composições para a prevenção e/ou tratamento de distúrbios degenerativos do sistema nervoso central

Info

Publication number
BR112012009121A2
BR112012009121A2 BR112012009121A BR112012009121A BR112012009121A2 BR 112012009121 A2 BR112012009121 A2 BR 112012009121A2 BR 112012009121 A BR112012009121 A BR 112012009121A BR 112012009121 A BR112012009121 A BR 112012009121A BR 112012009121 A2 BR112012009121 A2 BR 112012009121A2
Authority
BR
Brazil
Prior art keywords
prevention
treatment
nervous system
central nervous
degenerative disorders
Prior art date
Application number
BR112012009121A
Other languages
English (en)
Inventor
Boyd Robert
Lee Gary
J Rybczynski Philip
Original Assignee
Amicus Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Amicus Therapeutics Inc filed Critical Amicus Therapeutics Inc
Publication of BR112012009121A2 publication Critical patent/BR112012009121A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D211/40—Oxygen atoms
    • C07D211/44—Oxygen atoms attached in position 4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/191—Carboxylic acids, e.g. valproic acid having two or more hydroxy groups, e.g. gluconic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/451—Non condensed piperidines, e.g. piperocaine having a carbocyclic group directly attached to the heterocyclic ring, e.g. glutethimide, meperidine, loperamide, phencyclidine, piminodine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D211/40—Oxygen atoms
    • C07D211/44—Oxygen atoms attached in position 4
    • C07D211/46—Oxygen atoms attached in position 4 having a hydrogen atom as the second substituent in position 4
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D211/60—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/92—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with a hetero atom directly attached to the ring nitrogen atom
    • C07D211/96—Sulfur atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Psychology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

NOVAS COMPOSIÇÕES PARA A PREVENÇÃO E/OU TRATAMENTO DE DISTÚRBIOS DEGENERATIVOS DO SISTEMA NERVOSO CENTRAL. A presente invenção provê novos compostos, bem como composições e métodos usando os mesmos, para a prevenção e/ou tratamento de distúrbios degenerativos do sistema nervoso central. Em particular, a presente invenção provê métodos de prevenção e/ou tratamento de doença de Parkinson.
BR112012009121A 2009-10-19 2010-10-05 Novas composições para a prevenção e/ou tratamento de distúrbios degenerativos do sistema nervoso central BR112012009121A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US25280309P 2009-10-19 2009-10-19
PCT/US2010/051447 WO2011049736A1 (en) 2009-10-19 2010-10-05 Novel compositions for preventing and/or treating degenerative disorders of the central nervous system

Publications (1)

Publication Number Publication Date
BR112012009121A2 true BR112012009121A2 (pt) 2017-08-29

Family

ID=43879775

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112012009121A BR112012009121A2 (pt) 2009-10-19 2010-10-05 Novas composições para a prevenção e/ou tratamento de distúrbios degenerativos do sistema nervoso central

Country Status (27)

Country Link
US (4) US8604206B2 (pt)
EP (2) EP2490532B1 (pt)
JP (2) JP5805649B2 (pt)
KR (3) KR101813988B1 (pt)
CN (2) CN102655747A (pt)
AR (1) AR078606A1 (pt)
AU (3) AU2010308396B2 (pt)
BR (1) BR112012009121A2 (pt)
CA (1) CA2778348C (pt)
CY (1) CY1118966T1 (pt)
DK (1) DK2490532T3 (pt)
ES (2) ES2617192T3 (pt)
HK (1) HK1219724A1 (pt)
HR (1) HRP20170236T1 (pt)
HU (1) HUE033116T2 (pt)
IL (1) IL219160B (pt)
LT (1) LT2490532T (pt)
MX (2) MX340807B (pt)
PL (1) PL2490532T3 (pt)
PT (1) PT2490532T (pt)
RS (1) RS55679B1 (pt)
RU (2) RU2581058C2 (pt)
SG (1) SG10201507159XA (pt)
SI (1) SI2490532T1 (pt)
SM (1) SMT201700105B (pt)
TW (1) TWI642434B (pt)
WO (1) WO2011049736A1 (pt)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2490532B1 (en) 2009-10-19 2016-11-23 Amicus Therapeutics, Inc. Novel compositions for preventing and/or treating degenerative disorders of the central nervous system
PT2490533E (pt) 2009-10-19 2016-01-13 Amicus Therapeutics Inc Novas composições para a prevenção e/ou tratamento de distúrbios de depósito lisossómico
EP2591823A1 (en) * 2011-11-11 2013-05-15 Biologische Heilmittel Heel GmbH Composition for treating or preventing neurodegenerative disorders
WO2013148103A1 (en) 2012-03-27 2013-10-03 Amicus Therapeutics, Inc. Novel compounds for preventing and/or treating lysosomal storage disorders and/or degenerative disorders of the central nervous system
US9796680B2 (en) 2013-12-23 2017-10-24 Alectos Therapeutics Inc. Glucocerebrosidase modulators and uses thereof
US10179128B2 (en) 2015-08-31 2019-01-15 Amicus Therapeutics, Inc. Regimens for treating and preventing lysosomal disorders and degenerative disorders of the central nervous system
CN110573492A (zh) 2017-04-25 2019-12-13 阿米库斯治疗学公司 用于预防和/或治疗中枢神经系统退行性失调和/或溶酶体贮积失调的新颖组合物
RU2676956C1 (ru) * 2017-08-25 2019-01-11 Общество с ограниченной ответственностью "Международный Биотехнологический Центр "Генериум" Антитела для связывания имиглюцеразы и их применение в аффинной хроматографии
KR101991276B1 (ko) 2018-01-19 2019-06-21 전남대학교산학협력단 신규 균주 페니실리움 아쿠아티쿰 및 이를 이용한 퇴행성 뇌질환 치료제
US20220184185A1 (en) 2018-07-25 2022-06-16 Modernatx, Inc. Mrna based enzyme replacement therapy combined with a pharmacological chaperone for the treatment of lysosomal storage disorders
WO2024163532A1 (en) * 2023-01-31 2024-08-08 Bioeutectics Corporation Use of additives (adjuvants, anti freezing agents, antimicrobial and antioxidants) in natural deep eutectic solvents and mixtures

Family Cites Families (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4407957A (en) 1981-03-13 1983-10-04 Damon Corporation Reversible microencapsulation of a core material
WO1992019195A1 (en) 1991-04-25 1992-11-12 Brown University Research Foundation Implantable biocompatible immunoisolatory vehicle for delivery of selected therapeutic products
US5383851A (en) 1992-07-24 1995-01-24 Bioject Inc. Needleless hypodermic injection device
US5569189A (en) 1992-09-28 1996-10-29 Equidyne Systems, Inc. hypodermic jet injector
ATE220327T1 (de) 1992-09-29 2002-07-15 Inhale Therapeutic Syst Pulmonale abgabe von aktiven fragmenten des parathormons
US5863903A (en) 1994-03-09 1999-01-26 Novo Nordisk A/S Use of hydroxy alkyl piperidine and pyrrolidine compounds to treat diabetes
WO1995024391A1 (en) 1994-03-09 1995-09-14 Novo Nordisk A/S Piperidines and pyrrolidines
FR2718357B1 (fr) 1994-04-06 1997-10-03 Defarges Alain Moreau Perfectionnements apportés à un dispositif d'injection par jet sans aiguille.
US5599302A (en) 1995-01-09 1997-02-04 Medi-Ject Corporation Medical injection system and method, gas spring thereof and launching device using gas spring
US5780014A (en) 1995-04-14 1998-07-14 Inhale Therapeutic Systems Method and apparatus for pulmonary administration of dry powder alpha 1-antitrypsin
US5654007A (en) 1995-06-07 1997-08-05 Inhale Therapeutic Systems Methods and system for processing dispersible fine powders
TW498067B (en) * 1996-07-19 2002-08-11 Hoffmann La Roche 4-hydroxy-piperidine derivatives
US6274597B1 (en) 1998-06-01 2001-08-14 Mount Sinai School Of Medicine Of New York University Method of enhancing lysosomal α-Galactosidase A
AU2003273762A1 (en) * 2002-10-28 2004-05-13 Novo Nordisk A/S Use of glycogen phosphorylase inhibitors for treatment of cardiovascular diseases
US20040082641A1 (en) 2002-10-28 2004-04-29 Rytved Klaus Asger Use of glycogen phosphorylase inhibitors for treatment of cardiovascular diseases
US7446098B2 (en) 2003-02-18 2008-11-04 Mount Sinai School Of Medicine Of New York University Combination therapy for treating protein deficiencies
MXPA06007378A (es) 2003-12-23 2007-01-26 Musc Found For Res Dev Metodos y composiciones para la prevencion y tratamiento de enfermedades o condiciones inflamatorias.
US7501439B2 (en) 2006-05-24 2009-03-10 Amicus Therapeutics, Inc. Tartrate salt of isofagomine and methods of use
ES2364586T3 (es) * 2006-05-24 2011-09-07 Amicus Therapeutics, Inc. Sal tartrato de isofagomina y métodos de uso.
US7829579B2 (en) 2006-06-23 2010-11-09 Amicus Therapeutics, Inc. Method for the treatment of neurological disorders by enhancing the activity of β-glucocerebrosidase
WO2008134628A2 (en) 2007-04-26 2008-11-06 Amicus Therapeutics, Inc. Dosing regimens for the treatment of lysosomal storage diseases using pharmacological chaperones
WO2010015816A2 (en) 2008-08-06 2010-02-11 Summit Corporation Plc Treatment of lysosomal storage disorders and other proteostatic diseases
WO2010118283A1 (en) 2009-04-09 2010-10-14 Amicus Therapeutics, Inc. Methods for preventing and/or treating lysosomal storage disorders
EP2416655B1 (en) * 2009-04-09 2014-06-25 Amicus Therapeutics, Inc. Methods for preventing and/or treating degenerative disorders of the central nervous system
EP2490532B1 (en) * 2009-10-19 2016-11-23 Amicus Therapeutics, Inc. Novel compositions for preventing and/or treating degenerative disorders of the central nervous system
PT2490533E (pt) 2009-10-19 2016-01-13 Amicus Therapeutics Inc Novas composições para a prevenção e/ou tratamento de distúrbios de depósito lisossómico
PT2490712E (pt) * 2009-10-19 2015-10-27 Amicus Therapeutics Inc Método para tratar a doença de alzheimer utilizando chaperones farmacológicos para aumentar a atividade de gangliosidases
KR102023720B1 (ko) 2012-09-03 2019-09-20 엘지이노텍 주식회사 보이스 코일 모터

Also Published As

Publication number Publication date
ES2617192T3 (es) 2017-06-15
AU2016203817B2 (en) 2017-09-07
US9409862B2 (en) 2016-08-09
AU2017272296B2 (en) 2019-07-11
EP2490532B1 (en) 2016-11-23
HK1219724A1 (zh) 2017-04-13
HRP20170236T1 (hr) 2017-04-07
EP3143875B1 (en) 2020-05-27
AU2016203817A1 (en) 2016-06-30
KR20180001588A (ko) 2018-01-04
SG10201507159XA (en) 2015-10-29
EP2490532A4 (en) 2013-06-12
RU2015147509A (ru) 2019-01-14
MX2012004548A (es) 2012-07-04
PL2490532T3 (pl) 2017-05-31
MX340807B (es) 2016-07-27
JP2013508366A (ja) 2013-03-07
RS55679B1 (sr) 2017-07-31
AR078606A1 (es) 2011-11-23
KR20170096220A (ko) 2017-08-23
CN102655747A (zh) 2012-09-05
US10421724B2 (en) 2019-09-24
KR101813988B1 (ko) 2018-01-02
SI2490532T1 (sl) 2017-03-31
US20180273474A1 (en) 2018-09-27
PT2490532T (pt) 2017-02-23
US8604206B2 (en) 2013-12-10
IL219160A0 (en) 2012-06-28
US20140080871A1 (en) 2014-03-20
EP2490532A1 (en) 2012-08-29
KR101880411B1 (ko) 2018-07-19
AU2017272296A1 (en) 2018-01-25
CA2778348A1 (en) 2011-04-28
US20110092541A1 (en) 2011-04-21
JP2015157822A (ja) 2015-09-03
DK2490532T3 (en) 2017-02-27
CN105367485B (zh) 2018-04-17
JP5805649B2 (ja) 2015-11-04
KR20120104549A (ko) 2012-09-21
WO2011049736A1 (en) 2011-04-28
CA2778348C (en) 2022-08-23
EP3143875A1 (en) 2017-03-22
IL219160B (en) 2018-12-31
CY1118966T1 (el) 2018-01-10
LT2490532T (lt) 2017-03-27
JP6258245B2 (ja) 2018-01-10
KR101769396B1 (ko) 2017-08-18
AU2010308396B2 (en) 2016-04-28
CN105367485A (zh) 2016-03-02
US20160326114A1 (en) 2016-11-10
HUE033116T2 (en) 2017-11-28
ES2814178T3 (es) 2021-03-26
MX368459B (es) 2019-10-03
AU2010308396A1 (en) 2012-05-03
RU2012120759A (ru) 2013-11-27
TW201116279A (en) 2011-05-16
RU2581058C2 (ru) 2016-04-10
TWI642434B (zh) 2018-12-01
SMT201700105B (it) 2017-03-08

Similar Documents

Publication Publication Date Title
BR112012009121A2 (pt) Novas composições para a prevenção e/ou tratamento de distúrbios degenerativos do sistema nervoso central
BR112012009123A2 (pt) novas composições para a prevenção e/ou tratamento de distúrbios de depósito lisossômico
TN2010000122A1 (en) Compounds and compositions as modulators of gpr119 activity
MX2009009491A (es) Compuestos y composiciones como moduladores de la actividad del gpr119.
CL2015000096A1 (es) Compuestos derivados de 4-metil-2,3,5,9,9b-pentaaza-ciclopenta[a]naftalenos, inhibidores de fosfodiestearasa 2 y/o 10; composicion farmaceutica; y su uso para prevencion o tratamiento de enfermedades del sistema nervioso, como deficiencia cognitiva, demencia, trastornos de ansiedad, enf. de alzheimer, enf. de parkinson, otros
IN2012DN02469A (pt)
WO2013061161A3 (en) New combination therapies for treating neurological disorders
MY159856A (en) Compounds, compositions and methods for protecting brain health in neurodegenerative disorders
ECSP10010226A (es) Compuestos derivados de amina para tratar enfermedades y trastornos oftálmicos
BR112012032778A2 (pt) "proteínas multiespecíficas e multivalentes"
EA200901032A1 (ru) Соединения и композиции в качестве модуляторов активности gpr119
MA32889B1 (fr) Composes de pyrazine comme inhibiteurs de phosphodiesterase 10
WO2014018881A8 (en) Atx modulating agents
EA201691121A1 (ru) Гидроксиамидные соединения пиримидина в качестве ингибиторов деацетилаз белков и способы их применения
EA201200473A1 (ru) Замещенные (гетероарилметил)тиогидантоины
BRPI0807987A2 (pt) Terapia de combinação para tratamento de distúrbios imunes.
IN2012DN02471A (pt)
BR112015017775A2 (pt) enzima cistationina beta-sintase para o tratamento de homocistinúria
MX370253B (es) Composiciones de compuestos de jasmonato y métodos de uso de las mismas.
BR112014024308A8 (pt) uso de neuregulina para tratar lesão de nervo periférico
EP2563794A4 (en) INHIBITORS OF TYROSINE KINASE PROTEIN ACTIVITY AND THEIR APPLICATIONS TO THE TREATMENT OF OPHTHALMIC DISORDERS
EA201492102A1 (ru) Антагонисты lingo-2 для лечения заболеваний, в которых участвуют двигательные нейроны
MX340536B (es) Terapia direccionada al receptor del factor de crecimiento epidermico (egfr).
WO2011014520A3 (en) Compounds and compositions as modulators of gpr119 activity
MA32416B1 (fr) 7-sulfanylmethyl-, 7-sulfinymethyl-et 7-sulfonylmethyl-indoles substitues et leur utilisation

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]
B08G Application fees: restoration [chapter 8.7 patent gazette]
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]

Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI

B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B15K Others concerning applications: alteration of classification

Free format text: AS CLASSIFICACOES ANTERIORES ERAM: A01N 43/40 , A61K 31/445

Ipc: C07D 211/60 (2006.01), C07D 211/44 (2006.01), C07D

B09B Patent application refused [chapter 9.2 patent gazette]
B09B Patent application refused [chapter 9.2 patent gazette]

Free format text: MANTIDO O INDEFERIMENTO UMA VEZ QUE NAO FOI APRESENTADO RECURSO DENTRO DO PRAZO LEGAL